Cargando…
Clinical characteristics and management of immune checkpoint inhibitor-related cardiotoxicity: A single-center experience
BACKGROUND: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy in the past decade and amplify T-cell-mediated immune responses by disrupting immunoinhibitory signals. The augmented T-cell immune response has led to a range of immune-related adverse effects (irAEs). Immune-related...
Autores principales: | Xiao, Junjuan, Li, Xingyu, Wang, Xuan, Guan, Yaping, Liu, Hairong, Liang, Jing, Li, Yan, Wang, Baocheng, Wang, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10115988/ https://www.ncbi.nlm.nih.gov/pubmed/37089888 http://dx.doi.org/10.3389/fcvm.2023.1093383 |
Ejemplares similares
-
Immune Checkpoint Inhibitors: Cardiotoxicity in Pre-clinical Models and Clinical Studies
por: Xu, Shirley, et al.
Publicado: (2021) -
Myocarditis and myositis/myasthenia gravis overlap syndrome induced by immune checkpoint inhibitor followed by esophageal hiatal hernia: A case report and review of the literature
por: Yin, Beibei, et al.
Publicado: (2022) -
Immune Checkpoint Inhibitor-Associated Cardiotoxicity in Solid Tumors: Real-World Incidence, Risk Factors, and Prognostic Analysis
por: Chen, Xue, et al.
Publicado: (2022) -
Cardiotoxicity Related to Immune Checkpoint Inhibitors: A Real-World Retrospective Analysis
por: She, Jianqing, et al.
Publicado: (2022) -
Cardiotoxicity induced by immune checkpoint inhibitor: The complete insight into mechanisms, monitoring, diagnosis, and treatment
por: Ganesh, Sridha, et al.
Publicado: (2022)